University of Chicago psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
University of Chicago is listed with 10 registered studies counted here, in Chicago, United States. By compound: 1 psilocybin, 6 MDMA and 3 LSD. By registry status: 10 completed. By phase: 5 early phase 1, 2 phase 1, 1 phase 2 and 2 not applicable. Reported start years run from 2010 (earliest) to 2025 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 10 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 1 |
| MDMA | 6 |
| LSD | 3 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Completed | 10 | 100% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 5 | 50% |
| Phase 1 | 2 | 20% |
| Phase 2 | 1 | 10% |
| Not applicable | 2 | 20% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Drug Effects on Mood and Behavior - Expectancy | NCT07061886 | Completed | Early Phase 1 | 2025-06-26 | LSD |
| Mood Effects of Serotonin Agonists: Depression | NCT07017478 | Completed | Early Phase 1 | 2025-06-09 | LSD |
| Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder | NCT05399498 | Completed | Phase 2 | 2023-11-01 | Psilocybin |
| Prosocial Effects of MDMA | NCT05948683 | Completed | Early Phase 1 | 2023-07-21 | MDMA |
| Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function | NCT05379959 | Completed | Early Phase 1 | 2022-05-11 | MDMA |
| Drug Effects on Interpersonal Interaction | NCT05123716 | Completed | Early Phase 1 | 2021-08-01 | MDMA |
| Mood Effects of Serotonin Agonists Extended | NCT03934710 | Completed | Phase 1 | 2019-04-20 | LSD |
| Effect of Stimulant Drugs on Social Perception | NCT03790618 | Completed | Phase 1 | 2016-06-01 | MDMA |
| Effects of MDMA on Emotional and Social Memories | NCT03050541 | Completed | Not applicable | 2014-12-01 | MDMA |
| Effects of MDMA on Social and Emotional Processing | NCT01849419 | Completed | Not applicable | 2010-07-01 | MDMA |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD